107 search results for: symposium

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

35 min

Pulmonology

Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

expert video

UCARE 2023: Neuronal Involvement in CSU

7 min

Dermatology

Dr. Kim provides a deep dive into the neuroimmune axis in CSU.

expert video

Barrier Tight Junction Disruption in Atopic Dermatitis

1 min

Dermatology

Explore tight junction function in the skin and the impact of its disruption in atopic dermatitis – a soundbite from the ESDR Symposium 2022.

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

expert video

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis

7 min

Dermatology

Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.

expert video

UCARE 2023: Panel Discussion/Q&A

13 min

Dermatology

Drs. Maurer, Ensina, Saini, and Kim provide expert insights to questions regarding emerging treatment, pathophysiology and neuronal sensitization in CSU.

expert video

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

1 min

Dermatology

Dr. Saini describes immune cells and mediators beyond mast cells that are also essential for helping to drive CSU pathology.

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: CanadaChange country/region